U.S. markets close in 5 hours 31 minutes
  • S&P 500

    3,678.03
    +9.02 (+0.25%)
     
  • Dow 30

    30,006.81
    +123.02 (+0.41%)
     
  • Nasdaq

    12,422.12
    +72.75 (+0.59%)
     
  • Russell 2000

    1,847.08
    +9.05 (+0.49%)
     
  • Crude Oil

    45.21
    -0.07 (-0.15%)
     
  • Gold

    1,839.40
    +9.20 (+0.50%)
     
  • Silver

    24.08
    +0.00 (+0.02%)
     
  • EUR/USD

    1.2171
    +0.0056 (+0.46%)
     
  • 10-Yr Bond

    0.9240
    -0.0240 (-2.53%)
     
  • GBP/USD

    1.3485
    +0.0109 (+0.82%)
     
  • USD/JPY

    103.7280
    -0.6960 (-0.67%)
     
  • BTC-USD

    19,401.74
    +452.49 (+2.39%)
     
  • CMC Crypto 200

    381.25
    +6.84 (+1.83%)
     
  • FTSE 100

    6,475.54
    +12.15 (+0.19%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

AKRX, HIIQ & AMRN - Class Action Update Bronstein, Gewirtz & Grossman, LLC

NEW YORK, NY / ACCESSWIRE / April 12, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Akorn, Inc. (AKRX)
Class Period:
August 1, 2018 - January 8, 2019
Deadline: April 22, 2019
For more info: www.bgandg.com/akrx

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Akorn's management misled investors concerning the severity of Akorn's manufacturing violations at its Decatur, Illinois facility; (2) Akorn's responses to the Food and Drug Administration's ("FDA") Form 483 - which contained a list of observations made by the FDA during its inspection of Akorn's Decatur, Illinois facility in April and May 2018 - would be deemed inadequate by the FDA; (3) Akorn repeatedly failed to correct manufacturing violations at this facility; (4) the foregoing would subject Akorn to heightened regulatory scrutiny by the FDA; and (5) as a result, Akorn's public statements were materially false and misleading at all relevant times.

Health Insurance Innovations, Inc. (HIIQ)
Class Period:
February 28, 2018 - November 27, 2018
Deadline: April 22, 2019
For more info: www.bgandg.com/hiiq

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) a substantial portion of Health Insurance Innovations' revenue was derived from third parties; (2) these third parties used deceptive tactics to sell Health Insurance Innovations' policies, including overstating the policy's coverage and/or selling under the licenses of employees who had no involvement in the underlying sales; (3) regulatory scrutiny of these third parties would materially impact Health Insurance Innovations' operations; and (4) as a result of the foregoing, defendants' positive statements about Health Insurance Innovations' business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Amarin Corporation (AMRN)
Class Period:
September 24, 2018 - November 8, 2018
Deadline:
April 23, 2019
For more info:
www.bgandg.com/amrn

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/539930/AKRX-HIIQ-AMRN--Class-Action-Update-Bronstein-Gewirtz-Grossman-LLC